论文部分内容阅读
目的检测急性冠脉综合征(ACS)患者经过辛伐他汀强化治疗后C反应蛋白(CRP)的变化,讨论强化他汀对ACS的治疗作用及安全性。方法 80例ACS患者随机分两组。A组在常规治疗基础上予辛伐他汀10 mg/d;B组予辛伐他汀40 mg/d。治疗4周,监测治疗前后CRP、TC、LDL-C,同时观察安全性。结果治疗后两组CRP、血脂均有不同程度下降(P<0.05)。与A组比较,B组下降更明显(P<0.05)。两组均无严重不良事件。结论强化辛伐他汀早期干预可显著降低ACS患者CRP及血脂水平,并具有良好的安全性。
Objective To investigate the changes of C-reactive protein (CRP) in patients with acute coronary syndrome (ACS) after intensive chemotherapy with simvastatin and to discuss the therapeutic effect and safety of statin therapy on ACS. Methods Eighty patients with ACS were randomly divided into two groups. In group A, simvastatin 10 mg / d was given on a routine basis and simvastatin 40 mg / d in group B. Treatment for 4 weeks, before and after treatment to monitor CRP, TC, LDL-C, while observing the safety. Results After treatment, the levels of CRP and blood lipid decreased in both groups (P <0.05). Compared with group A, the decrease in group B was more obvious (P <0.05). There were no serious adverse events in either group. Conclusions Early intervention with intensive simvastatin can significantly reduce CRP and blood lipid levels in patients with ACS and has good safety.